The introduction of monoclonal antibodies into the clinic has paved the way for new approaches to stem cell transplantation for patients with lymphoma. These approaches include the development of new high-dose regimens with radiolabeled antibodies, in vivo purging techniques with the unlabeled antibodies, and posttransplant adjuvant immunotherapy. Numerous trials have demonstrated the feasibility of these approaches. However, questions remain regarding the application of these antibodies including the ultimate efficacy. The recent results of the incorporation of monoclonal antibodies into stem cell transplantation and current research directions are reviewed. Bone Marrow Transplantation (2001) 1 This publication met with significant optimism as it described a new way to specifically target and destroy malignant cells using murine MAB. In 1979 the first attempt at MAB therapy was undertaken. Unfortunately, however, the early clinical trials were not as successful as originally anticipated. Obstacles included the immunogenicity of the murine MAB which shortened the serum half-life and prevented repeat dosing, inadequate fixation of human complement, and the inability to fully activate host antibody-dependent cellular cytotoxicity (ADCC).
genicity and thus permitted multiple dosing, increased the serum half-life and allowed for the fixation of complement and activation of ADCC. In addition, significant insight has been gained into what constitutes an appropriate target. As most lymphomas are of B cell origin, B cell antigens such as CD20 and CD22 have become popular choices. These advances have resulted in MAB becoming effective tools alone or in combination with chemotherapy frequently employed in the treatment of lymphoma. 5 Many MAB products presently are approved for clinical use or in various stages of approval, and include radioimmunoconjugates with various isotopes as well as 'naked' antibodies ( Table  1 ). The development of murine and humanized MAB has opened the way for several improvements in the peripheral blood and marrow transplantation of lymphoma, which will be reviewed herein.
Radioimmunoconjugated MAB
As outlined above, the clinical utility of murine monoclonal antibodies was limited by the short half-life, immunogenicity, and difficulty with fixing complement and effecting ADCC. An alternative approach is to attach a source of radiation emission to the antibody as a way of giving targeted radiation therapy. A radiolabeled antibody does not need to rely upon complement fixation or activation of ADCC for an anti-tumor effect. Such preparations generally are given only once and thus immunogenicity is less problematic. In addition, the relatively short half-life becomes an advantage because a relatively briefer time in the circulation is desirable. Radiolabeled antibodies may also be more effective than their unlabeled counterparts because they do not have to reach every malignant cell to be effective. 6 Depending on the radioisotope used, the radiation can have an effect over 1 to 5 mm or more. Studies with 131 I-radiolabeled B cell antibodies indicate that significant dose escalation with radioimmunoconjugates is clearly possible with autologous stem cell transplantation. In a phase I study, Press et al 7 infused 12 patients with an anti-B1 131 I antibody at increasing doses in successive cohorts of patients with non-Hodgkin's lymphoma (NHL). Subsequently, the patients were infused with a marrow purged with anti-B cell antibodies. The maximum tolerated dose (MTD) was found to be 27.25 Gy. The lungs were the most common organ to receive dose-limiting radiation. These investigators subsequently conducted a phase II study of anti-B1 131 I antibody that confirmed the MTD of 27 Gy. Sixteen of 21 patients achieved complete remissions, two patients achieved partial remissions and one achieved a minor response. 8 In a combined analysis of the phase I and phase II patients, the progression-free survival was 51% at 4 years in patients with indolent lymphomas. 9 Building on their previous work, the Seattle Group has completed a phase I/II study combining the anti-B1 131 I antibody with high-dose cyclophosphamide and etoposide. 10 While the single agent anti-B1
131
I antibody when given in myeloablative doses appears promising, many patients relapsed from this therapy. In addition, most successful regimens for lymphoma require combinations of anti-neoplastic agents. In this study, 52 patients with relapsed B cell lymphoma received a therapeutic infusion of anti-B1 131 I antibody. The amount of 131 I varied according to dose level and was calculated based on the amount of radiation delivered to a critical organ such as the liver or lungs. Afterwards, the patients received dose level-specific doses of cyclophosphamide and etoposide. The maximum tolerated doses of these agents when used in combination was found to be 25 Gy of anti-B1 131 I with 60 mg/kg of etoposide and 100 mg/kg of cyclophosphamide. Remarkably, the MTD of anti-B1 131 I when used in combination was not that much lower than when used as a single agent. The estimated overall and progression-free survivals were 83% and 63%, respectively, which were superior to historical controls that received cyclophosphamide, total body irradiation (1200 cGy) and etoposide.
The best choice of radioisotope for high-dose therapy is unknown (Table 2 ). An alternative to 131 I is 90 Y. Studies ϩ NHL. Ten patients were primary refractory, seven patients were in first relapse, while in the six remaining patients remission status was greater than first relapse. Successive cohorts of patients received increasing doses of radiation (30-75 Gy) based on whole body dosimetry. The patients had rapid engraftment with neutrophil recovery on day 10 and platelet recovery on day 12. At the time of the last analysis there was one early death and 12 patients in complete remission or unconfirmed complete remission.
Phase I-II studies have been conducted with 90 Y-labeled antiferritin and autologous bone marrow rescue in patients with refractory Hodgkin's disease. A variety of schedules and doses were used. One patient received 50 mCi in a single dose. Other patients received a total of 80 mCi administered in two doses of 40 mCi each. Since these patients received autologous marrow support, it is not clear that the regimen was truly myeloablative. Furthermore, the maximum tolerated dose (MTD) was never reached. 13 A 12 patient feasibility study has also been conducted with 90 Ylabeled antiferritin and cyclophosphamide, carmustine, and etoposide in patients with refractory Hodgkin's disease. Patients received between 18 and 33 mCi. Four of the 12 patients died early of transplant-related causes while three remained in remission for longer than 2 years. 15 There are ongoing studies using the 90 Y-labeled anti-CD22 and 90 Y anti-CD20 to determine the MTD with autologous stem cell support.
Unlabeled antibodies
The 'humanization' of monoclonal antibodies and the subsequent clinical efficacy found with these naked antibodies made possible the incorporation of these antibodies into autologous stem cell transplant regimens. In general two approaches have been taken: in vivo purging and post-transplant adjuvant immunotherapy. The use of autologous stem cells, either marrow or peripheral blood, is complicated by the potential for re-introduction of malignant cells into the patient along with the autologous hematopoietic stem cell graft. Treating the autologous stem cell graft with MAB specific for B cell antigens is one way of removing undesired neoplastic stem cells from the autologous graft. In vitro antibody purging of bone marrow in the course of autotransplantation has been demonstrated to be effective in follicular lymphomas. 16 Gribben et al demonstrated that successful purging of a marrow graft using monoclonal antibodies in vitro is associated with improved disease-free survival. Autologous marrow grafts from 114 B cell malignancy patients were purged in vitro with a cocktail of anti-B cell monoclonal antibodies (anti-B1, anti-B5, anti-J5). The efficacy of the marrow treatment was assessed by the polymerase chain reaction (PCR) of marrow specimens before and after the purge. Purging resulted in a greater than three log reduction of lymphoma cell contamination and in 57 of the patients no residual neoplastic cells could be identified. Detection of residual lymphoma cells in marrow after purging was associated with a 39% relapse rate after a median follow-up of 23 months vs a 5% relapse rate in patients whose marrows showed no residual lymphoma (P Ͻ 0.00001). Long-term follow-up studies indicate that these remissions are durable. 17 Perhaps by giving a patient the monoclonal antibody one could purge the peripheral blood and consequently the stem cell graft in vivo. The first attempt with in vivo purging actually took place in chronic lymphocytic leukemia not lymphoma. Campath-1H is a 'humanized' monoclonal antibody directed against the CD52 antigen, commonly and intensely expressed on B cell malignancies including CLL. 18 It is also crossreactive with normal B cells and T cells. The Campath monoclonal antibodies have been used in numerous bone marrow transplant trials, usually to prevent graft-versus-host disease or in vitro for tumor purging. However, Dyer et al 19 demonstrated the feasibility of using this antibody as an 'in vivo' purging agent in patients who had residual disease after being treated to maximum response with purine nucleoside analogs. Five patients achieved hematologic and histologic complete remission following treatment with Campath-1H and one patient had minimal focal residual disease. These responses allowed for peripheral blood stem cell harvests subsequently to be performed. A phase II study is currently underway within the Eastern Cooperative Oncology Group (E8998) evaluating Campath-1H as an in vivo purging agent.
Rituximab, the anti-CD20 monoclonal antibody approved for the treatment of low grade and follicular lymphoma, has been more widely used. 20 This antibody induces ADCC, activates complement and directly induces apoptosis. [21] [22] [23] In vitro, rituximab has been shown to sensitize chemotherapy-resistant cell lines to chemotherapy. 24 It
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In an effort to exploit the known in vitro synergy with chemotherapy, Flinn et al 25 studied 25 patients with lowgrade and mantle cell lymphoma. Rituximab was administered 3 days prior to cyclophosphamide to mobilize stem cells. Filgrastim was administered subcutaneously at 10 /kg/day starting on the day after chemotherapy and continuing until completion of leukapheresis. Patients received an additional dose of rituximab 375 mg/m 2 7 days after hematopoietic reconstitution and platelet transfusion independence. Twenty-three of 25 patients were transplanted after harvesting at least 2.0 ϫ 10 6 CD34 cells/kg. The stem cell graft contained a median 1.07 ϫ 10 7 CD34 cells/kg. Six of seven stem cell products tested were free of tumor contamination using a sensitive PCR assay. The patients subsequently received high-dose therapy with either cyclophosphamide and total body irradiation or busulfan and cyclophosphamide. No significant increase in toxicity was noted with addition of this therapy to the standard transplant regimen. Specifically, no significant infections were seen in the first 60 days post transplant. However, transient neutropenia occurred in 25% of patients approximately 100 days post transplant. This neutropenia was transitory and resolved spontaneously or with filgrastim. One patient developed progressive pancytopenia and died on day 232 of multisystem organ failure.
A similar in vivo purging approach was used by Magni et al. 26 Fifteen patients with CD20 positive mantle cell or follicular lymphoma, bone marrow involvement and PCRdetectable molecular rearrangement received four sequential treatments with chemotherapy, three of which were followed by infusion of a growth factor and two doses of rituximab. While the antibody was given after chemotherapy, given the tight sequencing of the subsequent chemotherapy, it is likely that significant levels of rituximab were present at the time of the next chemotherapy. These patients were compared to 10 control patients prospectively treated with an identical chemotherapy regimen but without rituximab therapy. The stem cells from both groups were CD34 selected if there was residual neoplastic cells detectable by PCR. The CD34-positive cells harvested from the patients who received both chemotherapy and rituximab were PCR-negative in 93% of cases (vs 40% of controls; P ϭ 0.007 ). In addition, the stem cell grafts from increasing numbers of patients became PCR negative with successive chemotherapy and rituximab. Specifically, 10 of 15 patients' stem cell grafts were PCR negative after cyclophosphamide and two doses of rituximab. However, only one of these same 10 patients' stem cell grafts was PCR positive after subsequently receiving cytarabine and rituximab. It is not clear whether the addition of more antibody or chemotherapy after the administration of the antibody is the key factor. Preliminary results from a study in which patients' stem cells are mobilized with growth factors and rituximab without chemotherapy suggests that the chemotherapy may play an important part in combination with the antibody.
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Post-transplant MAB therapy
The use of monoclonal antibodies before transplant has two effects. The first, discussed above, is to purge the graft in vivo. The second effect is to increase the efficacy of the high-dose therapy. Depending on how closely the high-dose therapy follows the administration of the last dose of the antibody, there are likely to be measurable serum levels of the MAB at the time of the preparative regimen. Therefore, the monoclonal antibody therapy may increase the effect of the high-dose preparative regimen by sensitizing the neoplastic cells as has been demonstrated in vitro. Less is known about using monoclonal antibodies as post-transplant adjuvants. However, results from the pivotal trial that led to the approval of rituximab in the United States clearly indicate that the antibody is efficacious in patients who relapse with a follicular lymphoma after autologous stem cell transplant. Preliminary data are available from Horwitz et al 27 who are examining the use of rituximab in the posttransplant setting. Twenty patients with B cell NHL received 4 weekly infusions of rituximab 375 mg/m 2 40 days after infusion of the autologous stem cell grafts. Later patients also received a second course of rituximab 6 months after transplant. There were no grade 3-4 infusional toxicities seen. Nine of 20 patients developed 13 episodes of grade 3-4 neutropenia between 60 and 210 days post transplant. The episodes of neutropenia resolved except for one episode of febrile neutropenia and one episode of varicella-zoster virus infection being the only clinically significant complications. 27 The efficacy of this approach is not yet known.
Future directions
The introduction of monoclonal antibodies into the clinic has brought with it significant potential for improved transplant approaches for patients with lymphoma. However, numerous questions need to be answered before these approaches can be considered part of the routine care of the patient (Table 3) . Included in these questions are the integration of naked and radiolabeled antibodies, the choice of isotope, the choice of antibody or antibodies, and the timing of the administration of the antibody. A better understanding of how the naked antibodies work in humans may significantly influence the latter question. Clearly the Patients with relapsed large cell lymphoma will be randomized to receive a standard autologous transplant, or a standard autologous transplant with rituximab. Ritux ϭ rituximab; CY ϭ cyclophosphamide; PBSCT ϭ peripheral blood stem cell transplantation. optimum time of antibody administration would be different if the predominant mechanism of action is ADCC than if it is apoptosis. Studies are currently underway examining the role of hematopoetic growth factors in augmenting ADCC post transplant. The choice of antibody or antibodies will not be trivial as increasing numbers of antibodies make their way into the clinic. Data from early in vitro purging studies indicate that combinations of antibodies appear superior to single antibodies. 16 This finding may hold true for in vivo purging or even post-transplant immunotherapy. However, regardless of the specific regimen that is used ultimately, an improvement in survival needs to be demonstrated before these regimens can be considered efficacious. ECOG and the CALGB have proposed a trial of pre-and post-transplant immunotherapy with rituximab in patients with relapsed large cell lymphoma. This study will randomize patients to either six doses of rituximab, four during stem cell mobilization and two post transplant, with a standard high-dose regimen, or the standard high-dose regimen without rituximab (Figure 1 ). The primary endpoint of this study is survival. It is important also to recognize that the use of monoclonal antibodies in transplantation regimens were first developed in lymphoma because of the ready availability of antibodies for lymphoma as well as the established role of high-dose therapy for lymphoma. As antibodies become available for other hematologic and nonhematologic malignancies, the lessons learned in lymphoma will be applied to these diseases as well. Without a doubt, the incorporation of monoclonal antibodies in highdose therapy is an exciting new approach with significant potential to improve survival for patients undergoing these treatments.
